Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Top Cited Papers
Open Access
- 19 February 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 7 (1), 10690
- https://doi.org/10.1038/ncomms10690
Abstract
Cancer therapy has traditionally focused on eliminating fast-growing populations of cells. Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a ‘persister’ state of negligible growth. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance mechanisms. However, the diversity of drug-resistance mechanisms that can expand from a persister bottleneck is unknown. Here we compare persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies acquired diverse resistance mechanisms, including the most commonly observed clinical resistance mechanisms. Thus, the drug-tolerant persister state does not limit—and may even provide a latent reservoir of cells for—the emergence of heterogeneous drug-resistance mechanisms.Keywords
This publication has 42 references indexed in Scilit:
- Converting Cancer Therapies into Cures: Lessons from Infectious DiseasesCell, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNVBioinformatics, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Fast and accurate long-read alignment with Burrows–Wheeler transformBioinformatics, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Tumor heterogeneity: Causes and consequencesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007